Investment Rating - The report maintains a "Recommend" rating for the non-bank financial sector, indicating a positive outlook for investment in this area [1][8]. Core Insights - The non-bank financial sector is experiencing a continued high level of activity, with significant increases in holdings in both the brokerage and insurance segments. The brokerage sector's holdings increased to 0.99%, while the insurance sector saw a substantial rise to 2.04% [1][7]. - The overall fund net asset value reached 36.8 trillion yuan, reflecting a year-on-year growth of 14% and a quarter-on-quarter increase of 2% [12]. - The brokerage sector is expected to benefit from improved market conditions, with a projected net profit increase of 26% year-on-year for Q4 2025 [19][20]. - The insurance sector is poised for strong performance in 2026, driven by favorable market conditions and a significant increase in new policy premiums [22][23]. Summary by Sections Public Fund Market Size - As of Q4 2025, the total net asset value of public funds was 36.8 trillion yuan, with a year-on-year increase of 14% and a quarter-on-quarter increase of 2% [12]. - The non-monetary fund size reached 21.7 trillion yuan, growing 16% year-on-year [12]. Non-Bank Sector Holdings Analysis Brokerage Sector - The brokerage sector's holdings increased to 0.99%, up 0.1 percentage points from the previous quarter, with a total of 7.71 billion shares held, reflecting a 17.9% quarter-on-quarter increase [20]. - Major brokerages such as CITIC Securities and Guotai Junan saw significant increases in their holdings, with respective increases of 0.14 and 0.07 percentage points [20][21]. Insurance Sector - The insurance sector's holdings rose to 2.04%, a significant increase of 0.97 percentage points from the previous quarter, exceeding the benchmark allocation [23]. - Key players like Ping An and China Life experienced notable increases in their holdings, with Ping An's allocation rising by 0.68 percentage points [23]. Investment Recommendations - The report suggests focusing on key stocks within the brokerage sector, including Guotai Junan, CITIC Securities, and Huatai Securities, as well as major insurance companies like Ping An and China Life [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6030） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列中信証券股份有限公司（「本公司」）在上海證券交易所網站刊登的本公司關於間 接子公司發行中期票據並由全資子公司提供擔保的公告，僅供參閱。 承董事會命 中信証券股份有限公司 董事長 張佑君 中國北京 2026年1月26日 於本公告刊發日期 ，本公司執行董事為張佑君先生 、鄒迎光先生及張長義先生；本公司非執行董事為李艺女士 、 梁丹先生、張學軍先生、付臨芳女士及趙先信先生；本公司獨立非執行董事為李青先生、史青春先生、張健華 先生、劉俏先生及李蘭冰女士；及本公司職工董事為施亮先生。 证券代码：600030 证券简称：中信证券 公告编号：临2026-006 中信证券股份有限公司 关于间接子公司发行中期票据 并由全资子 ...

证券代码：600030 证券简称：中信证券 公告编号：临2026-006 中信证券股份有限公司 关于间接子公司发行中期票据 并由全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | 本次担保金额 | 实际为其提供的担保余额 | 是否在前期 | 本次担保是 | | --- | --- | --- | --- | --- | --- | | | | | （不含本次担保金额） | 预计额度内 | 否有反担保 | | CSI MTN | Limited | 500万美元 | 34.85亿美元 | 是 | 否 | 累计担保情况 | 对外担保逾期的累计金额（万元） - | | | --- | --- | | 截至本公告日上市公司及其控股子 公司对外担保总额（亿元） | 2,095.42 | | 对外担保总额占上市公司最近一期 经审计净资产的比例（%） | 71.49 | | | 担保金额（含本次）超过上市公司最近一期经审计净 | | | 资产50% | | ...

禾迈股份首次公开发行股票募集资金总额为55.78亿元，扣除发行费用后募集资金净额为54.06亿 元。该公司最终募集资金净额比原计划多48.48亿元。禾迈股份于2021年12月15日披露的招股说明书显 示，该公司拟募集资金5.58亿元，拟分别用于禾迈智能制造基地建设项目、储能逆变器产业化项目、智 能成套电气设备升级建设项目、补充流动资金。 禾迈股份首次公开发行股票的发行费用总额为1.72亿元，其中，承销费及保荐费1.42亿元。 中国经济网北京1月26日讯 禾迈股份(688032.SH)今日收报111.50元，跌幅7.04%。该股目前处于破 发状态。 2024年6月13日，禾迈股份公告分红方案，每10股派息(税前)36元，转增4.9股，除权除息日为2024 年6月19日。 禾迈股份于2021年12月20日在上交所科创板上市，发行价格为557.80元/股，发行股票数量为 1000.00万股，保荐人（主承销商）为中信证券股份有限公司，保荐代表人为金波、董超。 (责任编辑：何潇) 2022年5月30日，禾迈股份公告分红方案，每10股派息(税前)30元，转增4股，除权除息日为2022年 6月7日。 2023年6月6日，禾 ...

Group 1 - The company Longxin Technology (龙芯中科) expects to achieve an operating revenue of approximately 635 million yuan in 2025, representing a year-on-year growth of about 26% [1] - The projected net profit attributable to the parent company for 2025 is expected to be around -449 million yuan, which indicates a reduction in losses by approximately 176 million yuan compared to the previous year, a year-on-year decrease in losses of about 28% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be around -503 million yuan, which is a reduction in losses of approximately 162 million yuan compared to the previous year, reflecting a year-on-year decrease in losses of about 24% [1] Group 2 - Longxin Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 24, 2022, with an issuance of 41 million shares at a price of 60.06 yuan per share [2] - The total amount raised from the initial public offering (IPO) was approximately 2.462 billion yuan, with a net amount of about 2.419 billion yuan, which is 1.091 billion yuan less than originally planned [2] - The company intended to raise approximately 3.512 billion yuan for advanced process chip research and industrialization projects, high-performance general-purpose graphics processing unit chip and system research projects, and to supplement working capital [2]

中国经济网北京1月26日讯 必贝特(688759.SH)近日发布2025年年度业绩预亏公告。 经财务部门初步测算，必贝特预计2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露 数据）相比，将出现亏损，实现归属于母公司所有者的净利润为-16,600万元到-13,600万元；归属于母 公司所有者扣除非经常性损益后的净利润-18,800万元到-15,800万元。本次业绩预告情况未经注册会计 师审计。 2022年至2024年，必贝特均无营业收入，净利润/归属于普通股股东的净利润分别为-18,833.88万 元、-17,275.51万元、-5,599.83万元；扣除非经常性损益后归属于普通股股东的净利润分别为-20,749.04 万元、-18,776.76万元、-15,804.87万元；经营活动产生的现金流量净额分别为-12,766.89万 元、-12,737.30万元、-8,961.35万元。 必贝特于2025年10月28日在上交所科创板上市，发行股票数量9,000.0000万股，发行价格为17.78元/ 股，保荐机构（主承销商）为中信证券股份有限公司，保荐代表人为彭浏用、熊志兵，联席主承销商为 国信证 ...

Group 1 - The capital market has been active recently, with brokers conducting research on 440 A-share companies this year, predominantly in the electronics and machinery sectors, while the power equipment and chemical sectors have seen a surge in interest [1] - According to Founder Securities, brokers are still in a "lagging" phase, but ROE is on an upward trend, indicating that sector performance, although delayed, is expected to improve [1] - The capital market is projected to remain robust in 2025, with an average daily stock trading volume of 20.8 trillion yuan, a year-on-year increase of 70.2%, and an average margin balance of 2.08 trillion yuan, up 32.7% year-on-year [1] Group 2 - The 国证证券龙头指数 (399437) has shown a strong increase of 1.98%, with notable gains in constituent stocks such as 财通证券 (6.50%), 兴业证券 (4.95%), and 华泰证券 (3.52%) [1] - The 证券ETF鹏华 (159993) closely tracks the 国证证券龙头指数 and aims to reflect the market performance of quality listed companies in the securities theme [2] - As of December 31, 2025, the top ten weighted stocks in the 国证证券龙头指数 account for 79.13% of the index, including companies like 东方财富, 中信证券, and 华泰证券 [2]

Core Viewpoint - The current timing for increasing allocation in the consumer chain is now, particularly around the important meetings in March, with a focus on "expected trading" [1] - The real estate chain may also see significant recovery during this period, indicating that the building materials sector has already started to respond to domestic new construction [1] Group 1: Consumer Sector Insights - The food and beverage industry has undergone continuous adjustments for five years, aligning with characteristics of "low expectations, low holdings, and low valuations," suggesting that pessimistic expectations are already reflected in stock performance [1] - Historical data shows that sectors experiencing declines for 3-4 years often see reversals, with leading gains this year observed in sectors such as non-ferrous metals, chemicals, power equipment, and pharmaceuticals, all of which had previously adjusted for over three years [1] Group 2: Investment Strategies - It is challenging for individual investors to accurately identify "bottom-fishing" signals in the food and beverage sector; therefore, utilizing industry-themed ETFs, such as the food and beverage ETF, can help capture the potential reversal opportunities [1] - The food and beverage ETF tracks the largest sub-index of the food sector, including leading companies in various segments such as liquor, dairy, soft drinks, condiments, and snacks, featuring stocks like Kweichow Moutai, Luzhou Laojiao, Haitian Flavoring, Yili, Dongpeng Beverage, and Angel Yeast, making it a suitable tool for low-threshold investment in leading companies [1]

其锂电池智能装备产品涵盖电动汽车、储能、消费电子等应用领域，覆盖磷酸铁锂、三元等技术路线及 各类电池形态，并能提供固态电池制造设备。客户包括宁德时代、特斯拉、大众汽车、比亚迪等全球领 先企业。 先导智能通过港交所主板上市聆讯。中信证券、摩根大通为联席保荐人。 先导智能作为智能装备企业，为锂电池、光伏电池、3C制造、智能物流、制氢及燃料电池生产、汽车 制造和激光精密加工等多元应用领域提供智能装备及解决方案。该公司通过深度集成数据驱动算法、数 字孪生仿真等技术，赋能客户实现高自动化生产，降低人工成本，提升生产效率。 根据弗若斯特沙利文的资料，按2024年收入计，先导智能是全球第二大新能源智能装备供应商，市场份 额为2.9%。在锂电池智能装备市场，先导智能按2024年收入计为全球最大的供应商（市场份额 15.5%），同时也是中国最大的供应商（市场份额19.0%）。 在光伏领域，先导智能提供光伏组件和光伏电池制造的整线解决方案及单体装备，并成功交付 TOPCon、HJT、xBC、钙钛矿等新型光伏电池技术的GW级方案，客户包括通威太阳能、隆基绿能等行 业龙头。 （文章来源：证券时报网） ...

Core Viewpoint - The recent release of the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry" by the Ministry of Commerce and nine other departments aims to enhance the pharmaceutical retail sector through various measures, including improving pharmaceutical service capabilities and promoting prescription circulation [1][2]. Group 1: Policy Initiatives - The "Opinions" propose to enhance pharmaceutical service capabilities, promote prescription circulation, optimize designated pharmacy outpatient coordination, establish a commercial insurance payment guarantee system, improve health services, diversify pharmaceutical retail formats, and support the merger and reorganization of retail pharmacies [2][3]. - The encouragement of collaboration between qualified medical institutions, internet hospitals, and retail pharmacies through electronic prescription platforms is expected to accelerate prescription circulation and outpatient coordination in pharmacies [3]. Group 2: Industry Impact - The policy is likely to benefit leading retail pharmacies by enhancing their market share during the industry consolidation phase, as the optimized licensing process for merged pharmacies will allow for the continuation of existing medical insurance qualifications [3]. - The development of insurance products tailored for pharmacy scenarios and the establishment of health stations for chronic disease management and medication guidance will enable retail pharmacies to better meet the growing health service demands [3]. Group 3: Future Outlook - The acceleration of the "four modernizations" (professionalization, intensification, digitization, and standardization) in the pharmaceutical retail sector aligns with the broader healthcare reform goals outlined in the "14th Five-Year Plan," indicating a new phase for medical reform in China [4]. - The encouragement of industry concentration through the recent policy is expected to provide foundational support for the separation of medical services and the implementation of tiered diagnosis and treatment [4].